acasti pharma stock price target

Acasti Completes Acquisition of Grace Therapeutics Inc. NASDAQACST to Post FY2026 Earnings of 025 Per Share Oppenheimer Forecasts.

Wait For Acst Stock To Fall Further Then Pick Up Some Shares Investorplace

Stock quotes are provided by Factset Morningstar and SP Capital IQ.

. Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. Acasti Pharmas current and average target prices are 118 and 600 respectively. Current Price Target Price.

Is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. ET by Tomi Kilgore Acasti Pharma downgraded to neutral from buy at B. To contextualize these metrics consider that out of Healthcare stocks Acasti Pharma Incs average analyst price target is greater than 709 of them.

The average twelve-month price target for Acasti Pharma is 600 with a high price target of 600 and a low price target of 600. This is why it happened. Oppenheimer analyst Leland Gershell initiated coverage of Acasti Pharma with an Outperform rating and 6 price target.

Find the latest Acasti Pharma Inc ACST stock price forecast 12-month price target predictions and analyst recommendations. Evolution of the average Target Price on ACASTI PHARMA INC. Acasti Pharma ACST soars 207 premarket after Oppenheimer launched coverage at Outperform with price target of 6Acastis merger with Grace Therapeutics gives it.

The biopharmaceutical companys stock. PRE MARKET Vol 1. Target Price consensus revisions.

The company is now focused on the development of medicines for rare conditions and each of its candidates may offer meaningful advantages over standard-of-care while mitigating development risk and cost Gershell tells investors in a research note. Analyst Recommendations on ACASTI PHARMA INC. The community is currently still undecided about Acasti Pharma Inc with 1 Buy predictions and 0 Sell predictions.

The Company is targeting three underserved orphan diseases. According to the issued ratings of 1 analysts in the last year the consensus rating for Acasti Pharma stock is Buy based on the current 1 buy rating for ACST. ACST has a higher upside potential average analyst target price relative to current price than 8193 of Healthcare stocks.

ACST was reported by Oppenheimer on December 22 2021. February 15 2022. Now that we know that Oppenheimer is bullish on ACST stock lets take a look at other analysts price targets.

Acasti Pharma stock price target cut to 2 from 8 at B. The stock price of Acasti Pharma Inc NASDAQ. The 6 price target imputed a 44054 upside to the previous close.

Acasti Pharma Target Price Projection. The latest price target for Acasti Pharma NASDAQ. Outperform - Market Perform.

ACST analyst stock forecast price target and recommendation trends with in-depth analysis from research reports. Analyst Estimates Rating WSJ. AT CLOSE 400 PM EST 021422.

According to analysts consensus price target of 600 Acasti Pharma has a forecasted upside of 4263 from its current price of 114. On ACSTs analyst rating history. The Companys novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of.

Acasti Pharma Price Predictions HC. As a result the target price of 200 shows a very positive potential of 100000 compared to the current price of 100 for Acasti Pharma Inc. 2 days agoAcasti Pharma Inc.

On the other hand Acasti Pharmas target price is what analysts think the stock is worth or could sell for in the future. Acasti Pharma Inc. Investors are responding positively to Oppenheimer analyst Leland Gershell initiating coverage of Acasti Pharma with an Outperform rating and a 6 price target.

ACST Acasti Pharma Inc. ACST increased by 5225 in the previous trading session. Amount of Analyst Coverage Acasti Pharma has only been the subject of 1 research reports in the past 90 days.

PRE MARKET 445 AM EST 021522. The Best Blue-Chip Stocks. 14 2020 at 856 am.

Find the latest Acasti Pharma Inc. The analyst firm set a price target for 600 expecting ACST to rise to within 12. NASDAQ Updated Feb 16 2022 1248 AM ACST 128 006 492.

Rating and a 600 price target on the stock. Last 18 months Recommendations Chart ACASTI PHARMA INC. The current price of Acasti Pharma is the price at which Acasti Pharma is currently trading.

Todays 52-Week Highs. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Acasti Pharma Inc have a median target of 600 with a high estimate of 600 and a low estimate of 600. Subarachnoid Hemorrhage SAH Ataxia Telangiectasia A-T and Postherpetic Neuralgia PHN.

In terms of price targets and recommendations offered by analysts the stocks in the Pharmaceutical.

Earnings Whisper Number For Acst Acasti Pharma